Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Nomad Power Solutions, Inc. NMAD

19 fiscal years on record · USD · FY2025 reported · SEC filings only
$-6.1M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

The Company’s drug product pipeline is primarily focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. The Company is focusing on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity. LB-100 is currently being tested in clinical trials in Ovarian Clear Cell Carcinoma, Metastatic Micro Satellite Stable (MSS) Colon Cancer, and Advanced Soft Tissue Sarcoma. LB-100 has FDA Investigational New Drug status in the US and Investigational Medicinal Product Dossier approval in the European Union.

Written from the business description in Lixte Biotechnology Holdings, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 31 March 2026. Every sentence was checked against that document before publication.

Growth

·
Revenue, FY2025 · full 19-year series below
Revenue $M Net income $M
FY2015 · Revenue 0.2 · Net income -2.9
-2M-3M
2007201020132016201920222025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
ROE
FY2025 · ROE -115.9%
-500%-1000%
200720162025
Three returns, three denominators.

Each USD of equity lost 116 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Net buybacks $M Dividends $M
FY2018 · Dividends · · Net buybacks -4.5
-2M-4M
2018

Total assetsUSD 12.7M
EquityUSD 9.7M
Current ratio3.88×

Equity funds 76% of total assets.

The 19-year record

19 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
NMAD, 19-year financial record
Metric 2025202420232022202120202019201820172016201520142013201220112010200920082007
Revenue $B◌◌◌◌◌◌◌◌◌◌0.0◌0.00.00.00.0◌◌◌
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌◌
EBITDA $B◌◌◌◌◌◌◌◌◌◌◌◌−0.0−0.0−0.0−0.0◌◌◌
Income tax $B0.0◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−1.26−1.59−2.66−3.99−0.50−0.29−0.22−0.04−0.03−0.04−0.06−0.06−0.03−0.09−0.06−0.03◌◌◌
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend———————————————————
ROE %−115.9−148.7−111.1−126.8−137.3−87.7−74.4−83.3−299.0−810.0−986.6−1101.8−159.1−455.7−227.8−58.0——−437.4
Shares out B0.010.000.000.020.010.010.070.070.060.050.050.050.040.040.040.04◌◌◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 66 reconciliationsAUDITED

Reconciled in 19 of the 19 fiscal years we could check. Seven checks were skipped: cost of revenue is not tagged before 2014. Six checks were skipped: the balance sheet is not tagged before 2010. Four checks were skipped: the share count is not tagged before 2011.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2007

Share this section

Download image